Ann: Results of LCT Parkinsons trial require further analysis, page-101

The company was only interested in the top line data, I hear what you are saying Whytee , the DSMB have veto the placebo patients , as would have no medical benefit. Asked what would happen if new data from detailed analysis comes to light? LCT said that would then require a new trial to be developed to investigate ?
Also the asked why not use the TH and replied will take a lot longer than a weekend to complete detailed analysis , I wish u luck ,,, the question at the AGM will be Funding , and so close to this trial and the fall out for the next couple of weeks , the market will want to see significant change , that means someone at LCT will have to front up for the 80% loss , shareholder value wiped out, personally think Imupell should have been spun out on its own to other cell replacement clinics , was told it's not that simple , so Imupell has been tainted with the NTCell results , plus the company will have to lay some staff off , possible redundancies$$ you know what the market will want, Change,,, 11 years no commercial products is the track record